Trials / Recruiting
RecruitingNCT05909501
Assessment of Geriatric Evaluations Impact on New AML Guidance
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Conditions
Timeline
- Start date
- 2023-10-25
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2023-06-18
- Last updated
- 2025-08-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05909501. Inclusion in this directory is not an endorsement.